.svg)
Our mission is to treat osteoarthritis and get people moving without pain.
about
Sparta is creating the first-of-its-kind chemically engineered cartilage platform, Galene.
The degeneration of cartilage between the joints can cause significant personal, economic, societal burden for individuals, families, and communities. In addition, acute injuries to joint cartilage can exacerbate and become debilitating over time.
We are developing cartilage-like implants for the knee and all of the important joints in the body.
Galene is a Multi-Indication Platform
Leadership team
We are a team of operators, technologists, scientists, and engineers with long histories in the pharma, medtech, and nuclear arenas, and are driven by a common purpose; we seek to advance the standard of care for osteoarthritis and get people moving again without pain.
Would you like to be considered for the clinical trial?
Click the button below and fill out the form.
Clinical need
We all have friends and family who are suffering from knee pain and limited range of motion. This is not only a problem locally, but globally. Over 651M suffer from osteoarthritis (OA). There are 16M visits in the US specifically for knee symptoms. In addition, there are hundreds of thousands osteochondral repairs per year. Unfortunately, there is a high percentage of patients who have a revision within two years. In addition, there are several million people getting a total knee replacement each year. A third of them were considered inappropriate candidates for this intervention. This issue also afflicts active military. Limited duty days exceed 1M after chondral procedures. One in three veterans have OA. The overall prevalence of knee cartilage lesions in high performance athletes is almost 40%.
our approach
The condition of any given joint is not just a result of chronological age, but also biological age - prior injury, daily routine, profession, and diet.
Galene, our proprietary bionic cartilage, renders biological age irrelevant.
Unlike cartilage regeneration technologies which take months, if not years, to fully regenerate cartilage, Galene replicates the physical properties of native human hyaline cartilage immediately. With optimized geometry based on anatomical locations, our technology has the potential to allow us to precisely and effectively address the needs of patients afflicted with osteoarthritis and cartilage defects, providing patients with immediate pain reduction and full range of motion, resulting in a quality of life they deserve.
The OrmiTM implant, a Breakthrough Device, was created by combining Galene with an osseointegrative titanium base. OrmiTM is intended to treat chondral and osteochondral lesions of the femoral condyle.
The Treatment Gap
Current technologies and treatments for cartilage defects have severe limitations. Click here to learn about the different surgical treatments available, and how they fall short next to Ormi™.
Clinical Benefit
A Target Product Profile (TPP) is a set of outcomes that focuses our efforts on building a solution that meaningfully improves that standard of care. Along with satisfying many safety requirements, we set a high bar on those outcomes that matter most for patients. Our TPP is unmatched by existing treatments and technologies in development. We believe this will instill confidence in surgeons as they help their patients quickly resume their daily routines and while knowing many productive years lay ahead.
Surgeons can take comfort in knowing their patients will quickly resume their routines and have highly productive lives many years to come.
Pipeline
We are building a substantial pipeline of OrmiTM solutions. We will leverage all the know-how and preclinical testing from our knee indication and create efficient and cost effective development paths for these additional indications.
PRESS RELEASES
RESOURCES
Contact us
We will send you an email when we have updates to share.
